Organovo (NASDAQ:ONVO) vs. Palisade Bio (NASDAQ:PALI) Head-To-Head Survey

Organovo (NASDAQ:ONVOGet Free Report) and Palisade Bio (NASDAQ:PALIGet Free Report) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, institutional ownership, profitability, earnings, valuation, analyst recommendations and dividends.

Institutional and Insider Ownership

9.1% of Organovo shares are owned by institutional investors. Comparatively, 1.9% of Palisade Bio shares are owned by institutional investors. 4.0% of Organovo shares are owned by insiders. Comparatively, 1.3% of Palisade Bio shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.


This table compares Organovo and Palisade Bio’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Organovo -4,061.12% -129.61% -105.15%
Palisade Bio N/A -93.04% -78.63%

Analyst Recommendations

This is a summary of current recommendations and price targets for Organovo and Palisade Bio, as reported by

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Organovo 0 0 0 0 N/A
Palisade Bio 0 0 1 0 3.00

Palisade Bio has a consensus price target of $8.75, suggesting a potential upside of 1,888.64%. Given Palisade Bio’s higher possible upside, analysts clearly believe Palisade Bio is more favorable than Organovo.

Valuation & Earnings

This table compares Organovo and Palisade Bio’s gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Organovo $370,000.00 24.42 -$17.26 million ($2.14) -0.42
Palisade Bio N/A N/A -$14.26 million N/A N/A

Palisade Bio has lower revenue, but higher earnings than Organovo.

Volatility and Risk

Organovo has a beta of 0.91, suggesting that its stock price is 9% less volatile than the S&P 500. Comparatively, Palisade Bio has a beta of 1.42, suggesting that its stock price is 42% more volatile than the S&P 500.


Palisade Bio beats Organovo on 7 of the 10 factors compared between the two stocks.

About Organovo

(Get Free Report)

Organovo Holdings, Inc., a biotechnology company, focuses on developing 3D tissues that recapitulate key aspects of human disease. Its 3D human tissue platform includes its proprietary NovoGen Bioprinters, which are automated devices that enable the fabrication of 3D living tissues comprised mammalian cells; and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture. The company offers ExVive 3D bioprinted human liver tissue with distinct hepatocellular and non-parenchymal cell compartments. The company was incorporated in 2007 and is headquartered in San Diego, California.

About Palisade Bio

(Get Free Report)

Palisade Bio, Inc., a clinical-stage biopharmaceutical company, focuses on focuses on developing therapeutics that protect the integrity of the intestinal barrier in the United States. The company's lead therapeutic candidate is LB1148, an oral liquid formulation of the digestive enzyme inhibitor tranexamic acid to reduce the formation of postoperative adhesions, postoperative ileus, and return of bowel function in adults. It has a license agreement with the Regents of the University of California; and co-development and distribution agreement with Newsoara Biopharma Co., Ltd. Palisade Bio, Inc. is based in Carlsbad, California.

Receive News & Ratings for Organovo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Organovo and related companies with's FREE daily email newsletter.